LIITA Care enters an exclusive distribution agreement with Apotekernes Amba for BREATHOX®
BREATHOX® is a Danish invention, that allows the user to inhale micronized salt. This new treatment form clinically proven to clean the...
Who we are
Our proprietary technology is safe and effective
We are world's first company to introduce salt particle inhalation to the market
Dry NaCl powder inhaler
BREATHOX® is a dry NaCl powder inhaler containing micronized NaCl inhalable size ; 1-10 μm
The worlds only...
BREATHOX® is the worlds only medical device that dispense a metered dose of NaCl particles into the upper and lower airways
Cleaning airways
BREATHOX ® promotes the cleaning of the airways and relieves respiratory tract irritation and mucus accumulation
Natural Self-care Product
BREATHOX® supports the growing trend of natural therapies and self-care treatment in the consumer healtcare market
Improving life through better breathing
At LIITA Care, we are developing novel therapies that improve the lives of people suffering from respiratory diseases
Achievement
Life Is In The Air
We have developed a novel treatment platform, that enables respiratory self-care patients to adopt first line ‘standard of care’ outside of hospitals
We aspire...
to make the world a better place – to breathe
For chronic patients, such as:
-
COPD patients
-
Cystic Fibrosis patients
-
Asthma patients
For temporary patients, such as:
-
Common Cold patients
-
Covid-19 patients
-
Pollution victims
-
Smokers
What We Do
Creating respiratory self-care solutions
We are focused on creating a respiratory self-care portfolio, based on our proprietary inhalation technology, for larger consumer healthcare players to bring to market
Products
-
Dry/Wet Salt
-
Nasal/Oral
Indications
-
Antiviral
-
Anti-inflammatory
-
Pediatric
Latest News
Catch up on the latest news & updates here
05 September 2022 • Press Release
New Scientific Discovery Points Toward a Natural Solution for Mild to Moderate Covid-19 Patients
We are proud to announce that our latest scientific discovery was selected by the European Respiratory Society to be presented as Late-Breaking Abstract in the category ‘Best abstracts in COVID-19’ at the forthcoming ERS International Congress in Barcelona.
“We see ERS’ acceptance as an endorsement of our research and the vast treatment potential that the result implies,” says CEO Martin A. Ohrt“ We hope that the publication of our discoveries in the anti-viral field will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form”
“Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19“ is presented by Investigation Leader Pr. Suzana Erico Tanni (UNESP, Brazil).
02 September 2022 • Media Update
LIITA Research to be Presented at ERS Congress 2022
We are proud to announce that our latest scientific discovery was selected by the European Respiratory Society to be presented as Late-Breaking Abstract in the category ‘Best abstracts in COVID-19’ at the forthcoming ERS International Congress in Barcelona.
“We see ERS’ acceptance as an endorsement of our research and the vast treatment potential that the result implies,” says CEO Martin A. Ohrt“ We hope that the publication of our discoveries in the anti-viral field will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form”
“Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19“ is presented by Investigation Leader Pr. Suzana Erico Tanni (UNESP, Brazil).
Come join us Monday the 5th of September at 12.45 pm (Room 8L).
2022 • News Article
Stay tuned for more news
TBA
Browse All News
Latest News
Catch up on the latest news & updates here
Latest News
Catch up on the latest news & updates here